Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials - via The Oncologist. academic.oup.com/oncolo/advance…
#OCEPublications

Unraveling the Link: MUTYH mutations drive higher KRAS G12C prevalence, heightened tumor mutational burden, and unique mutational signatures across cancers. Fred R. Hirsch #MolecularBiology #Research doi.org/10.1093/oncolo…

Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study buff.ly/3EJmEGI

📚 🔬 Thrilled to share a new EORTC publication on The Oncologist:

' #QualityOfLife in Male #BreastCancer : Prospective Study of the International #MaleBreastCancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)'

👉 doi.org/10.1093/oncolo…

#CancerResearch #ClinicalTrials #Oncology

Agree completely. Words matter, and 'fail treatment' inevitably implies, however unintended, that the patient is somehow at fault. The Oncologist

Older Patients Are Comfortable With Telehealth and Prefer It as an Option - 92% of those over 70 say they are comfortable with telehealth. buff.ly/3mLB7fU

Patients are the greatest educators.
Every interaction with them is a learning experience. Let's continue to learn from their strength, resilience, and unique perspectives.
#patientexperience #education OncoAlert CancerDotNet Sumanta K. Pal, MD, FASCO Toni Choueiri, MD ASCO ESMO - Eur. Oncology Kidney Cancer

Congratulations to Susan Bates, MD, who has received the 2023 ESMO (ESMO - Eur. Oncology) Targeted Anticancer Therapies Honorary Award, recognizing her significant contributions to the field of anticancer drug development. 👏

Dr. Bates presents her award lecture today at #ESMOTAT23 .

Please all send us examples of PD1/L1 post PD/L1 failures from randomized trials where same control backbone in both arms. We need the help of the oncology community ! Thank you Oncology Brothers OncoAlert ASCO ESMO - Eur. Oncology Melanoma Research Foundation SWOG Cancer Research Network Alliance for Clinical Trials in Oncology ECOG-ACRIN Cancer Research Group NCICancerTrials

I am amazed & thrilled to have been selected for this important award, and am looking forward to being in Paris for the 2023 ESMO TAT meeting -- by my count it is TAT #20. Thank you ESMO! #ESMOTAT23

Important commentary on future directions in ctDNA assessment. May be an approach to identifying cancers with epigenetic origins. The Oncologist

An article from the February issue of The Oncologist reports on whether differences in patients’ race/ethnicity, preferred language, and other factors are associated with patient enrollment in oncology research studies. buff.ly/3m2Ayhd

In this commentary, Max Smith & William Douglas Figg, Sr discuss a recently published trial on #COMT genotype and #opioid dose requirements. They describe the current evidence & resources for opioid pharmacogenetic testing to improve #pain management. #PGx
doi.org/10.1093/oncolo…

Just in The Oncologist: In a large cohort of Black men with advanced #prostatecancer undergoing ctDNA profiling 👉Machine learning analysis shows ⬆️ frequency of AR, EGFR, MYC, FGFR1, CTNNB1 alterations in Black vs. White men👇bit.ly/3wHKRcM OncoAlert Pedro C Barata, MD MSc FACP Mehmet Asim Bilen,MD

🔘In this retrospective study
No increase in renal or non-renal immune-related side effects with immunotherapy in patients with stage 4-5 CKD (eGFR<30), which is usually the exclusion criterion in clinical trials
The Oncologist OncoAlert #MedTwitter ASCO
doi.org/10.1093/oncolo…

We really need to rethink language in Oncology.
➡️ We should not subgroup as Responders vs. Non-Responders.
➡️ they are not their stages of cancer. We don't enroll stage 4 anyone.
Remember people aren't their cancers.

Our terrific CTR editor at The Oncologist! The Oncologist

A recent meta-analysis including 13,929 patients in The Oncologist also supported routine genotyping The Oncologist academic.oup.com/oncolo/article…
Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy....... Sharma et al.